CAS: 5633-20-5; 4-(Diethylamino)But-2-Yn-1-Yl 2-Cyclohexyl-2-Hydroxy-2-Phenylacetate

该化合物是一种主要用于治疗过活膀胱和尿尿失禁的合成抗胆碱药物,其作用是抑制膀胱肌肉受体的乙酰胆碱酯酶作用,导致膀胱缩缩缩减少和膀胱容量增加.Oxybuynin的特点是其化学配方C18H21NO3,其分子重量约为301.37克/毫醇.它通常存在于各种配方中,包括即时释放和延长释放片以及跨度肾脏补补丁.该物质以其中度的脂性而著称,有利于其吸收和在体内的分布.普通副作用可能包括干口,静电,眩晕和模糊的视力,可归因于其抗胆碱性特性.Oxybutyyn主要在肝脏中代谢,其药性能可能受到诸如年龄和肝脏功能等因素的影响.

结构式图片

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号1508-65-2 盐酸奥昔布宁 | CAS号10575-25-4 4-二乙氨基-2-丁炔-1-醇 | CAS号4335-77-7 2-环己基-2-羟基苯乙酸 | CAS号22396-77-6 乙酸4-(二乙氨基)-2-丁炔醇酯 | CAS号10399-13-0 2-环己基-2-羟基苯乙酸甲酯 | CAS号10575-25-4 4-二乙氨基-2-丁炔-1-醇 | CAS号4335-77-7 2-环己基-2-羟基苯乙酸

合成工艺路线路线简述

    📜盐酸奥昔布宁 以 水 作为反应溶剂,化学反应 4.0H,反应生成 奥昔布宁
    参考文献:Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
    标题:Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
    摘要:提供一种含有涂层药物-离子交换树脂复合物的水性悬浮液,包括由苯丙胺与药用可接受离子交换树脂复合成的核和未涂层的苯丙胺-离子交换树脂复合物.涂层的苯丙胺-离子交换树脂复合物与聚合物混合形成基质.描述了制备涂层复合物和液体悬浮液的方法.

    海关参考信息

    专利信息


    专利号:US-6825378-B2
    优先权日:2003-03-28
    标 题 :Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid
    发明人:KUMAR PRADEEP; FERNANDES RODNEY AGUSTINHO; GUPTA PRITI
    权利人:COUNCIL SCIENT IND RES
    摘要:The present invention provides a process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid of formula (1). The present invention more particularly relates to a process using cyclohexylphenyl ketone for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid of formula (1).

    专利号:US-2024082118-A1
    优先权日:2021-05-19
    标 题:Topical compositions and methods of preparing the same
    发明人:ABRAMOVICH SAGI; AVIDOR GAL; LANDA BENZION
    权利人:LANDA LABS 2012 LTD
    摘要:There is disclosed a composition comprising a water-insoluble thermoplastic compound capable of stimulating collagen synthesis (CSSC), the CSSC having a molecular weight of more than 0.6 kDa and being dispersed in a polar carrier as nano-elements having an average diameter of 200 nm or less and a viscosity of 107 mPa·s or less. The nano-elements of CSSC can be capable of stimulating the synthesis of skin proteins and/or enabling the delivery of active agents upon their application to a surface to be treated therewith. Methods for preparing the compositions and uses thereof are also provided.

    专利号:WO-2017137955-A1
    优先权日:2016-02-14
    标题:Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
    发明人:THOMBARE PRAVIN SAHADEV
    权利人:CELESTIS PHARMACEUTICALS PVT LTD
    摘要:The present invention relates to novel chiral 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-amine (5) and racemic 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-amine () and its use in improved and industrially advantageous process for preparation of chiral and racemic form of 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol. Further, present invention relates to preparation of the same.

    专利号:US-6140529-A
    优先权日:1998-10-22
    标 题 :Synthesis of optically active cyclohexylphenylglycolate esters
    发明人:BAKALE ROGER P; LOPEZ JORGE L; MCCONVILLE FRANCIS X; VANDENBOSSCHE CHARLES P; SENANAYAKE CHRIS HUGH
    权利人:SEPRACOR INC
    摘要:A process for the preparation of optically active cyclohexylphenylglycolate esters is described. The process utilizes carboxylic acid activation to couple (R)- or (S)-cyclohexylphenylglycolic acid (CHPGA) with 4-N,N-diethylamino butynol or other propargyl alcohol derivatives. The preparation of the hydrochloride salt is also described. In addition, a resolution process employing tyrosine methyl ester enantiomers for preparing a single enantiomer of CHPGA from racemic CHPGA is disclosed.

    专利号:US-10022366-B2
    优先权日:2013-04-23
    标 题:Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
    发明人:STINCHCOMB AUDRA L; GHOSH PRIYANKA
    权利人:STINCHCOMB AUDRA L; GHOSH PRIYANKA; UNIV MARYLAND; UNIV KENTUCKY RES FOUND
    摘要:Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.

    专利号:US-10035796-B2
    优先权日:2014-08-14
    标题:Crystalline forms of a BACE inhibitor, compositions, and their use
    发明人:KAZAKEVICH IRINA; TRZASKA SCOTT; FENG TAO
    权利人:MERCK SHARP & DOHME
    摘要:The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Capalbo D, Guarino S, Di Sessa A, Esposito C, Grella C, Papparella A, Miraglia Del Giudice E, Marzuillo P. Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment. Eur J Pediatr. 2023 Jan 25. doi: 10.1007/s00431-023-04824-5. Epub ahead of print. 67(3):222-227. doi: 10.4103/ijd.IJD_799_20.
    5: Edwards BA, Joosten SA. Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine. Respirology. 2023 Mar;28(3):215-216. doi: 10.1111/resp.14395. Epub 2022 Oct 18. 28(3):273-280. doi: 10.1111/resp.14383. Epub 2022 Oct 2. Erratum in: Respirology. 2022 Oct 30;: 28(3):9-14. doi: 10.46292/sci21-00091. Epub 2022 Aug 17.
    8: Sun P, Wang Z, Wu T, Zuo S, Huang X, Cui Z, Zhang D. Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats. Front Bioeng Biotechnol. 2022 Jun 27;10:906835. doi: 10.3389/fbioe.2022.906835.

    合成参考文献


    参考文献:10.1155/2011/714978
    摘要:Masumori N, Miyamoto S, Tsukamoto T, Furuya S, Iwasawa A, Sato T, Itoh N, Shibuya A, Oda T. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. Adv Urol. 2011;2011():714978.
    参考文献:10.1179/2045772311y.0000000012
    摘要:Kennelly MJ, Bennett ME, Grill WM, Grill JH, Boggs JW. Electrical stimulation of the urethra evokes bladder contractions and emptying in spinal cord injury men: Case studies. The Journal of Spinal Cord Medicine. 2011 May;34(3):315–21. doi: 10.1179/2045772311y.0000000012.
    参考文献:10.1016/j.urology.2011.05.011
    摘要:Yoshida A, Seki M, Nasrin S, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Ehlert FJ, Yamada S. Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard. Urology. 2011 Sep;78(3):721.e7–721.e12. doi: 10.1016/j.urology.2011.05.011.
    参考文献:10.1007/s11255-011-0030-y
    摘要:Lehnert T, Weisser M, Till H, Rolle U. The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity. International Urology and Nephrology. 2011 Jul 21;44(2):335–41. doi: 10.1007/s11255-011-0030-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知